Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 5/20 | 0.45 |
| ▸ | BRD4 | O60885 | 5/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.38 |
| ▸ | ATIC | P31939 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158099 | 0.92 | BRD4 (0.54) | HTR6BRD4 | |
| SCHEMBL4155589 | 0.91 | ALDH1A1 (0.50) | HTR6BRD4POLBESR1ALDH1A1 | |
| SCHEMBL4155597 | 0.91 | HTR6 (0.45) | HTR6BRD4POLBESR1 | |
| SCHEMBL4169893 | 0.91 | BRD4 (0.53) | HTR6BRD4ESR1 | |
| SCHEMBL4162383 | 0.89 | MAPT (0.46) | HTR6BRD4ALDH1A1ATIC | |
| SCHEMBL4162539 | 0.89 | MEN1 (0.51) | HTR6BRD4 | |
| SCHEMBL4162564 | 0.89 | MAPT (0.48) | HTR6BRD4ALDH1A1HIF1A | |
| SCHEMBL4164244 | 0.89 | BRD4 (0.55) | HTR6BRD4ESR1ALDH1A1 | |
| SCHEMBL4162654 | 0.89 | BRD4 (0.55) | HTR6BRD4POLBALDH1A1HIF1A | |
| SCHEMBL4157748 | 0.87 | BRD4 (0.57) | HTR6BRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | BCL2 1073/4885BCL2L1 1132/4885MCL1 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.